Breaking News, Collaborations & Alliances

Gilead & Global Fund Partner for HIV Prevention

Gilead will supply enough lenacapavir doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead.

Author Image

By: Charlie Sternberg

Associate Editor

Gilead Sciences Inc. has partnered with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead. Under this strategic partnership agreement with the Global Fund, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters